TargetBeta
POLQ
DNA polymerase theta · also POLH · DNA polymerases
2 programs in company-led studies act on POLQ, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Polymerase Theta Helicase Inhibitor AZD4956 | AstraZeneca | inhibitor | phase 2 | 11 running | – | a judged reading |
| SYN818rule | Hangzhou SynRx Therapeutics Biomedical Technology | inhibitor | phase 1 | 22 running | – | the studies' text |
Conditions their studies are in
- Neoplasm Metastasis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Aug 25, 2028SYN818 · Hangzhou SynRx Therapeutics Biomedical Technology · phase 1 · NCT07156253
- Mar 29, 2030Polymerase Theta Helicase Inhibitor AZD4956 · AstraZeneca · phase 2 · NCT07446855
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.